scores in children with Hunter syndrome after 12 months of treatment. The key secondary endpoint evaluated the difference between the SHP609-treated and control groups as measured by the change ...

The UK regulatory authorities have approved the first ever trial of a revolutionary gene therapy for young children diagnosed with Hunter syndrome, a devastating rare lysosomal storage disorder. Five ...

Hunter syndrome can be diagnosed using the physical symptoms of children at the age of 18 months and 4 years. Treatments can help manage condition, no known cure Diagnosed by medical professional ...

Bow Hunter's Syndrome (BHS) is a rare condition characterized by vertebrobasilar insufficiency, which occurs when the vertebral artery is compressed during head rotation. This compression can lead ...

Hunter syndrome results from the absence of an enzyme needed to break down cellular waste. Without it, waste builds up in the body, causing progressive damage to various systems.

This is a retrospective study of the history, roentgenology and autopsy pathology when appropriate of all infants with severe respiratory-distress syndrome who required twenty-four hours or more ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

Hunter’s syndrome affects only about 1 in 162,000 ... life expectancy has been raised to 19 years old, however– lots of children pass with this disease around age 13. For McKay, the community ...